Skip to main content
. 2016 Jan 6;6:18633. doi: 10.1038/srep18633

Figure 3. VIP treatment increases the Treg/Th17 ratio and the expression of tolerogenic mediators at the implantation sites.

Figure 3

CBA/J × DBA/2 pregnant mice were treated in vivo with 2 nmol/mouse VIP or PBS i.p. at day 6.5 and the implantation sites were obtained at day 8.5. (A) Foxp3 and RORγt expression and (B) TGF-β and PPARγ expression were evaluated by RT-PCR. Bands were semi-quantified with ImageJ® and intensity expressed in arbitrary units (AU) relative to GAPDH. Values represent mean ± S.E.M of at least 3 experiments (Mann Whitney test *p < 0.05).